Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of atezolizumab in chemotherapy-naive stage IV PD-L1-high non-small cell lung cancer
CTR20213006Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jun 2022; status: active.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20213006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213006.